Patrick G. Enright's Insider Trades & SAST Disclosures
Patrick G. Enright's most recent trade in BioAge Labs Inc. was a trade of 5,848,637 Series D Preferred Stock done . Disclosure was reported to the exchange on Sept. 25, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Patrick G. Enright.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BioAge Labs Inc. | Patrick G. Enright | Director | 25 Sep 2024 | 5,848,637 | 0 | - | - | Series D Preferred Stock | ||
| BioAge Labs Inc. | Patrick G. Enright | Director | 25 Sep 2024 | 1,310,589 | 1,310,589 | - | - | Common Stock | ||
| BioAge Labs Inc. | Patrick G. Enright | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 25 Sep 2024 | 400,000 | 1,710,589 | - | 18 | 7,200,000 | Common Stock |
| BioAge Labs Inc. | Patrick G. Enright | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Sep 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharmaceuticals plc | Patrick G. Enright | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 3,731 | 24,677 (0%) | 0% | 0 | Ordinary Shares | |
| Vera Therapeutics Inc - Or... | Patrick G. Enright | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Jazz Pharmaceuticals plc | Patrick G. Enright | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2023 | 3,075 | 22,187 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Patrick G. Enright | Director | Sale of securities on an exchange or to another person at price $ 138.16 per share. | 11 Aug 2023 | 1,241 | 20,946 (0%) | 0% | 138.2 | 171,455 | Ordinary Shares |
| Vera Therapeutics Inc - Or... | Patrick G. Enright | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Vera Therapeutics Inc - Or... | Patrick G. Enright | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.00 per share. | 06 Feb 2023 | 1,714,285 | 1,714,285 | - | 7 | 11,999,995 | Class A Common Stock |
| Jazz Pharmaceuticals plc | Patrick G. Enright | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 2,561 | 25,175 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Patrick G. Enright | Director | Sale of securities on an exchange or to another person at price $ 152.33 per share. | 05 Aug 2022 | 1,089 | 24,086 (0%) | 0% | 152.3 | 165,883 | Ordinary Shares |
| Vera Therapeutics Inc - Or... | Patrick G. Enright | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 9,925 | 9,925 | - | - | Stock Option (right to buy) | |
| Vera Therapeutics Inc - Or... | Patrick G. Enright | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 10 Feb 2022 | 333,333 | 3,429,927 | - | 15 | 4,999,995 | Class A Common Stock |
| Jazz Pharmaceuticals plc | Patrick G. Enright | Director | Grant, award, or other acquisition of securities at price $ 137.75 per share. | 18 Aug 2021 | 2,000 | 2,000 (0%) | 0% | 137.8 | 275,500 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Patrick G. Enright | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2021 | 2,246 | 22,614 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Patrick G. Enright | Director | Sale of securities on an exchange or to another person at price $ 147.00 per share. | 12 Nov 2020 | 5,083 | 21,991 (0%) | 0% | 147.0 | 747,217 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Patrick G. Enright | Director | Sale of securities on an exchange or to another person at price $ 145.81 per share. | 12 Nov 2020 | 3,223 | 27,074 (0%) | 0% | 145.8 | 469,946 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Patrick G. Enright | Director | Sale of securities on an exchange or to another person at price $ 147.61 per share. | 12 Nov 2020 | 1,623 | 20,368 (0%) | 0% | 147.6 | 239,575 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Patrick G. Enright | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 9,929 | 30,297 (0%) | 0% | - | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Patrick G. Enright | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 9,929 | 0 | - | - | Phantom Stock | |
| Jazz Pharmaceuticals plc | Patrick G. Enright | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2020 | 6,765 | 6,765 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jazz Pharmaceuticals plc | Patrick G. Enright | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2020 | 2,705 | 20,368 (0%) | 0% | 0 | Ordinary Shares |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges